Combination Cancer Immunotherapy Market Expected To Surpass USD 15 Billion By 2028 Says Kuick Research
Singapore, June 09, 2022 (GLOBE NEWSWIRE) -- Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
-
Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
-
Global Combination Cancer Immunotherapy Market Opportunity: > USD 12 Billion
-
Combination Cancer Immunotherapy Market By Different Cancers
-
Patent, Price & Dosage Analysis On Approved Combination Drugs
-
Global & Regional Sales Insights On Approved Combination Drugs Till 2028
-
Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
-
Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
-
Clinical Trials & Patent Insight By Company, Country, Indication & Phase
Download Report:
https://www.kuickresearch.com/report-combination-cancer-therapy-market
The entrance of therapeutic antibodies has shown huge clinical success, making them one of the widely accepted drug class in the management of cancer. While therapeutic antibodies have shown success as monotherapy in some patients, treatment paradigms are trending towards employing them as combinational therapy with chemotherapy, radiation, molecularly targeted drugs such as tyrosine kinase inhibitors, other antibodies against the same target, immune checkpoint inhibitors, vaccines, and/or cellular therapies. These combinational strategies are currently undergoing both preclinical investigation and clinical trials in wide range of therapeutic indications.
Currently, various monoclonal antibodies including Herceptin, Rituxan, Erbitux, Monjuvi, Sarclisa, Arzerra, Danyelza, and others have been approved in combination with other cancer targeting regimens owing to their ability to enhance the survival outcomes in cancer patients. For instance in 2020, US FDA granted approval to fixed dose combination of Herceptin and Perjeta for the management of all stages of HER2-positive breast cancer in combination with chemotherapy. The drug is sold under the brand name Phsego and also be used in combination with Taxotere (docetaxel) to treat HER2-positive metastatic breast cancer that has not been treated with anti-HER2 therapy or chemotherapy. The introduction of monoclonal antibodies combination therapy has shown high adoption rates in wide range of cancers.
In addition to this, several ongoing clinical trials are also evaluating novel combinations which have shown encouraging preliminary response and are expected to gain entry into the market in the coming years. For instance, recent phase-II clinical trial demonstrated that the combination of tucatinib (Tuksya) and trastazumab (Herceptin) in patients with Her2 positive colorectal cancer. The combination was well tolerated and also led to enhance anti-tumor response among patients with significant increase in objective response rate and overall survival rate. It is estimated that more than 2000 clinical trials are ongoing in this segment, suggesting positive future of the market.